NextCure, Inc. (NXTC): Depreciation & Amortization
$2.20M
Year ended 2025-12-31
-18.7%
3-year compound annual growth
-8.3%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.20M | -24.1% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $2.90M | -21.6% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $3.70M | -9.8% | 2025-03-06, From 2023-01-01 |
| 2022-12-31 | $4.10M | -4.7% | 2024-03-21, From 2022-01-01 |
| 2021-12-31 | $4.30M | +26.5% | 2023-03-02, From 2021-01-01 |
| 2020-12-31 | $3.40M | +26.5% | 2022-03-03, From 2020-01-01 |
| 2019-12-31 | $2.69M | +60.3% | 2021-03-04, From 2019-01-01 |
| 2018-12-31 | $1.68M | n/a | 2020-03-12, From 2018-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| NextCure, Inc. (NXTC) | 2025-12-31 | $2.20M | -24.1% |
| Hyperion Defi, Inc. (HYPD) | 2024-12-31 | $1.13M | +44.1% |
| Actinium Pharmaceuticals, Inc. (ATNM) | 2025-12-31 | $173.0K | -12.2% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $199.0K | +32.7% |
| Akari Therapeutics Plc (AKTX) | 2024-12-31 | $14.0K | +250.0% |
| Spruce Biosciences, Inc. (SPRB) | 2025-12-31 | $21.0K | -54.3% |
| Medicinova Inc (MNOV) | 2025-12-31 | $20.1K | -4.6% |
| Connect Biopharma Holdings Ltd (CNTB) | 2025-12-31 | $704.0K | +6.7% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $1.29M | -27.5% |
Compare NXTC, HYPD, ATNM, VTGN side by side · Screen every company in Pharmaceutical Preparations ↗